Back
Full-text
Journal article

Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors.

  • König D Division of Medical Oncology, University Hospital Basel, Basel, Switzerland.
  • Läubli H Division of Medical Oncology, University Hospital Basel, Basel, Switzerland, heinz.laeubli@unibas.ch.
  • 2020-07-30
Published in:
  • Pharmacology. - 2020
Antibody
Autoimmune
B cell
Cross-presentation
Cytokine
Cytotoxic T-lymphocyte-associated antigen 4
Programmed cell death protein-1
T cell
English Immune checkpoint inhibitors (ICIs) have changed the prognosis of many cancer patients. Blocking antibodies targeting inhibitory cytotoxic T-lymphocyte-associated antigen 4 or programmed cell death protein-1 receptors or the programmed cell death ligand-1 have led to long-lasting remissions in patients with even advanced cancers. Main side effects induced by ICIs are inflammatory complications with sometimes severe sequelae for patients. Recent studies have improved our understanding how such immune-related adverse events (irAEs) develop. Here, we summarize the current knowledge of pathomechanisms involved in the de-velopment of irAEs with a particular focus on potential pathways that could be targeted to prevent severe immune-related complications in patients treated with cancer immunotherapy.
Language
  • English
Open access status
hybrid
Identifiers
Persistent URL
https://sonar.ch/global/documents/92633
Statistics
Document views: 99 File downloads:
  • Full-text: 0